1. Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.60
Figure 4 Effect of baseline RAVs on different direct-acting antiviral regimens
Figure 4 | Effect of baseline RAVs on different direct-acting antiviral regimens. a | The Gln80Lys (Q80K) polymorphism in the NS3 gene is present in approximately one-third of patients with HCV genotype 1a and affects response to simeprevir when combined with PEG-IFN and RBV. Data shown are from a pooled analysis of QUEST-1 and QUEST-2. b | Patients with HCV genotype 1a infection with cirrhosis were treated with simeprevir and sofosbuvir in the OPTIMIST-2 study. Those with the Gln80Lys (Q80K) mutation had lower SVR12 rates than those without the Gln80Lys (Q80K) mutation. c | Baseline NS5A RAVs are present in 10–15% of patients with HCV genotype 1 infection. The effect of RAVs on first-generation regimens such as asunaprevir/daclatasvir is apparent, even in genotype 1b infection, which is normally less of a challenge to treat than genotype 1a infection. Data from the HALLMARK-DUAL study. d | RAVs also have an effect on second-generation agents (grazoprevir or elbasvir) in patients with genotype 1a infection. e | However, RAVs have little effect on grazoprevir–elbasvir in patients with genotype 1b infection. Data from the C-EDGE trial. RAV, resistance-associated variant; RBV, ribavirin; SVR, sustained virologic response; SVR12, sustained virologic response at 12 weeks.
Götte, M. & Feld, J. J. (2016) Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro